In November 2019, the Italian Society of Endocrinology (SIE) has published a consensus statement on the tailoring of glucocorticoid replacement in adrenal insufficiency \[[@CR1]\]. A few months later, a novel severe acute respiratory syndrome coronavirus (SARS-CoV2) has been recognized as responsible for COVID-19. The outbreak has now reached pandemic level, with a high global mortality rate \[[@CR2]\]. From February on, Italy has experienced an exponential rise in the infected which is estimated to reach 200,000 people, with an overall lethality of approximately 10% \[[@CR3]\]. A recent Chinese series of nearly 50,000 patients with confirmed COVID-19 infection found that approximately one-out-of-five (19%) evolve towards severe (14%) or critical (5%) pneumonia \[[@CR4]\]. Several clinical trials are now testing the therapeutic options to treat lung and extra-respiratory complications of SARS-CoV2 infection. While awaiting for a specific treatment strategy, the SIE task force met again to address the tailoring of corticosteroid replacement in adrenal insufficient patients coping with the stress related to COVID-19 infection.

Pathophysiology of immune response in COVID-19 {#Sec2}
==============================================

Accumulating evidences have shown that COVID-19 infection follows a distinct but related stage progression. The acute respiratory distress syndrome (ARDS) observed in a significant proportion of fragile patients, roughly after the second week, is apparently non-exclusively related to uncontrolled viral replication, but rather to an out-of-control host response. The initial immune response, involving Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I), NOD-like receptors (NLRs), and other virus sensors in respiratory epithelial cells is critical in reducing the viral load and alerting the host \[[@CR5]\]. The response begins with the recruitment of innate immunity. If viral self-propagation is not limited, the increasing number of infected epithelial cells and cell debrides trigger a massive cytokine release---the so-called 'cytokine storm'---with hyperinflammation and immunosuppression, characterized by increased Th17 and CD8 cytotoxic activity and decreased memory CD4 + T helper cells \[[@CR6]\]. The antiviral immune response represents a balancing act between the elimination of virus and immune-mediated pulmonary injury. Pathology studies revealed that lung injury starts at the epithelial--interstitium--endothelial interface with increasing vascular permeability and extravasation of immune cells (mostly macrophages and granulocytes). The exudation reduces surfactant production in the alveolar space, impeding alveolar patency and gaseous diffusion \[[@CR7]\]. Infected epithelial cells and debris bind immune cell receptors, triggering the release of inflammatory cytokines (predominantly IL-6, IL-1 and TNF alpha) and activating fibroblasts. The second phase begins when uncontrolled viral propagation induces angiotensin-converting enzyme 2 (ACE2)-directed cytotoxicity, triggering a vicious circle leading to hyperactivation of immune cells and worsening the hyperinflammation state. Patients also show lymphopenia with reduced B Cells, CD4 and CD8 T cells and CD16^+^ Natural Killer cells count, probably due to an increase in extravasation of dysfunctional lymphocytes and inflammation-induced apoptosis \[[@CR8]\]. The cytokine storm leads to increased clotting, vascular inflammation, leading to disseminated thromboembolism, and hypotensive shock \[[@CR6], [@CR7]\]. Although a balanced immune response seems to keep the viral infection under control, a small fraction of patients evolves through all stages \[[@CR9]\]. In these critical cases, the priority following severe lung damage is to reduce hyperinflammation \[[@CR6]\] and thromboembolism that are associated the increase mortality.

Glucocorticoids in critical illness {#Sec3}
===================================

Exogenous glucocorticoids (GCs) have traditionally been associated with immune suppression. For this reason, their use has been discouraged, in the early days of the pandemic, fearing that they may favor viral propagation limiting the first line of defense, the innate immunity, that is also the most sensitive to GCs. If so, one would expect patients with chronic obstructive pulmonary disease, asthma or rheumatological disorders at an increased risk of severe COVID-19 presentation. Surprisingly, these comorbidities appear under-represented in patients with severe COVID-19 \[[@CR3], [@CR10]--[@CR12]\]. Although confounding factors and reporting bias could account for such findings, they suggest that GCs should not be blamed or discouraged. More, it cannot be excluded that GCs play a role in shaping the clinical presentation of COVID-19 \[[@CR12]\], and a retrospective study of 200 patients with ARDS apparently showed a lower mortality among those receiving methylprednisolone \[[@CR13]\]. The number of registered clinical trials on the use of steroids in COVID-19 pneumonia and related ARDS increases daily, aimed at investigating the effects of different formulations, associations and dosages. Due to their proved efficacy in different respiratory diseases, high lung bioavailability and strong anti-inflammatory efficacy, most on-going trials are focusing on methylprednisolone (NCT04263402, NCT04323592, NCT04343729, NCT04273321, NCT04244591), dexamethasone (NCT04327401, NCT04325061) and budesonide (NCT04331470) alone or in combination with other therapies targeting inflammation, such as Siltuximab (NCT04329650) or Tacrolimus (NCT04341038). The scope of this update, however, it to review the physiological role of cortisol that is missing in adrenal insufficient patients coping with COVID-19.

It is now recognized that GCs have both stimulating and inhibitory effects on immune response according to their timing and circulating levels \[[@CR14]\]. In the early phases of infections, physiological GC levels are necessary to prime the immune system. This, in turn, activates hypothalamic--pituitary--adrenal (HPA) axis to increase GC release from the adrenal glands aiming to reach higher concentrations responsible for mild immunosuppression, finally reducing autoimmunity and cytokine toxicity. This ability to reduce inflammation and, ideally, fibrosis has been the rationale for the use of GCs in lung damage so far, but the associated complications and the lack of a real benefit on overall survival---with possible harm also advocated, such as gastrointestinal bleeding, hepatic failure and thromboembolism---have relegated their use to refractory shock or (by some authors) ARDS, when lung damage approaches an irreversible threshold \[[@CR15]\]. Similarly, studies of high-dose GCs in sepsis are conflicting, with the REGARDS \[[@CR16]\] and the more recent ADRENAL trials \[200 mg hydrocortisone daily vs. placebo\] showing no beneficial effects on the 90-day mortality \[[@CR17]\], but with the APROCCHS trial showing a 28-day reduction in mortality of septic patients receiving hydrocortisone plus fludrocortisone therapy \[[@CR18]\].

One of the reasons underpinning the conflicting evidences published so far on steroid therapy in viral respiratory infections and pneumonia could lie in the heterogeneity of the studies included in the meta-analysis assessing the mixed results of the effects of different GCs formulations (both short and long acting), given without considering the two different pathophysiological phases of the infection. In fact, if in one hand, supraphysiological dose of exogenous GCs have been shown to exerts detrimental effects in the early phase (by increasing the plasma viral load), one can argue the possibility to restrain the cytokine storm of the second, and more harmful, phase suppressing the immune overreaction by steroid treatment \[[@CR19]\]. Moreover, in critically ill patients, the HPA axis may be unable to produce sufficient amount of corticosteroids, leading to critical illness-related corticosteroid insufficiency (CIRCI) \[[@CR20]\]. Although the pathological features and clinical progression of COVID-19 resemble those seen in other coronavirus infections for which various standardised steroid protocols have been proposed, recent WHO guidance on the clinical management of COVID-19 advises against corticosteroids, unless indicated for another reason \[[@CR21]\]. Adrenal insufficiency (AI) represent such a condition, in which the rationale to a prompt correction of GC therapy is not addressed to treat lung disease, but rather is aimed to supplement the abnormal adrenal function and, thus, to save patients' life. However, specific indications have been missing, and current standards of care actually suggest increasing the GC dose if COVID-19 infection is suspected, applying the "sick-day-rule" \[[@CR22]\].

COVID-19 in adrenal insufficiency do we need to change glucocorticoid therapy? {#Sec4}
==============================================================================

AI patients run an increased risk of infection due to their inefficient innate immune response, characterized by increased "classical" monocytes and decreased cytotoxic NK cells, with failure of IgG-mediated activation due to shedding of its surface receptor (CD16) \[[@CR23]\]. The disrupted immune response could also contribute to the worsening of COVID-19 infection into severe ARDS due to impaired first-line defence. Additionally, as previously mentioned, the HPA axis plays a significant role in stress-priming the immune response and the lack of physiological increase in GC secretion in AI patients during mild illness intuitively exposes them to higher risk of progressing to more critical stages, especially if replacement therapy is not properly administered. Moreover, as noted in other critical illnesses, COVID-19 pneumonia can affect residual adrenal function \[[@CR20]\] through cytokine release, worsening the outcome of patients with secondary AI. This is true also for tertiary adrenal insufficiency, the commonest cause for AI in the general population, resulting from long-term (more than 4 weeks) steroid treatment (equal or more than 5 mg of prednisolone per day), especially if administered in a non-circadian fashion (e.g., night doses).

This issue is of particular importance, as the sick day rules for GC therapy during infections are still largely tailored empirically, based on a few anecdotal case reports \[[@CR24]\] and disregarding timing and dosage \[[@CR1]\], and most patients with tertiary adrenal insufficiency are unaware or unprepared to handle stress-doses. It must to be taken into account that mild COVID-19 symptoms such as fatigue, malaise, gastrointestinal symptoms overlap with common symptoms experienced by AI patients, even outside adrenal crisis. This makes it difficult to establish when an increase in GC therapy is actually needed, and the patients' fears may lead them to increase their dose unnecessarily.

Despite the above mentioned reports of a lower representation of subjects taking low-dose GC among those with a more severely symptomatic COVID-19 \[[@CR3], [@CR10]--[@CR12]\], to date there is no evidence supporting a beneficial (nor a detrimental) role for corticosteroids in preventing viral infection or spread. More, considering that 60--80% of infected subjects remains completely asymptomatic \[[@CR4]\], there is no indication to increase GC therapy in asymptomatic patients with AI.

In contrast, for the symptomatic patients, establishing the correct timing of stress dose administration relative to the degree of inflammatory damage and the desired effect on the immune system is of paramount importance in COVID-19. Thus, there is no doubt that we must to be ready to increase GC dose in AI patients. The decision on how, when, how much to do so, requires attention and cannot be left to vague indications.

Management of glucocorticoid therapy in adrenal-insufficient patients with COVID-19 {#Sec5}
===================================================================================

Recent studies have provided further insight into GC metabolism during stress conditions. Hydrocortisone (HC) clearance significantly drops during stress challenges. In moderate stress, 100 mg followed by 60 mg/24 h of HC infusion generally maintains cortisol levels above normal the range in most of AI patients \[[@CR24]\]. Thus, in the early phase when patients might only develop mild COVID-19 related illness, characterized by uncomplicated upper respiratory symptoms (sore throat, nasal congestion, mild intermittent cough), with or without fatigue, malaise, anorexia, muscle ache, headache, mild nausea or diarrhoea, fever \< 38 °C and no signs of respiratory impairment, it appears safe to treat AI patients with low-to-intermediate additional doses (i.e., doubling the usual dose or adding oral 20--40 mg HC), to replace the missing stress-induced cortisol rise (Fig. [1](#Fig1){ref-type="fig"}). At this stage of mild illness, cortisol circadian rhythm should still be mimicked. Disturbances in circadian rhythm enhance inflammatory response to exogenous pathogens \[[@CR25]\] and, even in the absence of pathogenic challenge, they promote a shift towards a pro-inflammatory state and exhaustion of the counterregulatory mechanism necessary to drive host response \[[@CR26]\]. In trauma patients or bacterial infections, the disruption of circadian genes rhythmicity and the change in cortisol acrophase favor the development of shock \[[@CR27]\]. The indication is further strengthened by the observation that patients undergoing major cardiac surgery maintain some circadian rhythmicity, as the coupling between ACTH and cortisol secretion is maintained, even if blunted because of a higher basal cortisol secretion \[[@CR28]\]. Finally, GC excess is associated with a high prevalence of psychiatric (depression, mania, anxiety) and neurocognitive disorders \[[@CR29]\]. These can overlap with the psychological impact that the lockdown strategies have caused in many different socio-economical contexts; therefore, if not needed, it appears reasonable to avoid an excessive GC load. However, in a significant proportion (20%) of adrenal-sufficient subjects with COVID-19, the disease progresses to moderate or severe. No data are yet available in AI patients, therefore, it is mandatory that vital parameters, such as blood pressure (of utmost importance, as hypotension develops in the late phases), heart and respiratory rate and resting peripheral oxygen saturation, be monitored daily. In cases of incoming vomit (more than one day and especially within 3 h from the last steroid dose) and/or diarrhea, parenteral injection is mandatory. If fever increases or persists, symptoms worsen (including AI-specific signs and symptoms, such as incoming hypotension), or respiratory damage progresses with patients showing persistent cough, increased respiratory rate (\> 30 breaths per minute) and/or SpO2 less than 93%, (current definitions of moderate COVID-19 disease, see Fig. [1](#Fig1){ref-type="fig"}), GC therapy should be immediately increased to 100 mg (preferentially by parenteral administration according to the clinical status) and hospitalization is needed to be ready to face an adrenal crisis and start treatment to limit immune hyperactivation (see Fig. [1](#Fig1){ref-type="fig"}). Contrary to the general population, the threshold for hospitalization should be low for worsening symptoms in AI patients, considering their risk for an adrenal crisis.Fig. 1Proposal for a stage-specific adjustment of glucocorticoid therapy in adrenal insufficient patients with COVID-19 infection

In the hospital, if clinical condition worsens and moves towards ARDS, higher dose should be started. In this context, Prete et al. recently identified an initial bolus of 50--100 mg of hydrocortisone followed by continuous intravenous infusion of 200 mg (per day?) as the most appropriate regimen in AI patients with sepsis \[[@CR30]\]. This protocol is able not only to cover the amount of steroid needed to cope with the infection but also to reduce the harmful effects that peaks and troughs of GC therapy cause to the immune system \[[@CR30]\]. At this stage of disease, and for these steroid levels, circadian rhythm is no longer relevant. A very recent consensus on the management of critically ill adults with COVID-19 endorsed the same protocol in patients with refractory shock, as it is able to reduce the time to resolution and ICU length of stay \[[@CR31]\]. It also recommended the use of hydrocortisone rather than other synthetic compounds (as often used in ICUs). Although a detailed mention of the characteristics of the several steroid formulations is beyond the scope of this paper, one should bear in mind the different anti-inflammatory action between the available compounds.

Hydration and electrolyte balance should also be monitored and corrected promptly, as in the second stage, peripheral shock can cause severe hypotension, requiring pharmacological intervention. In critical setting, additional mineralocorticoid therapy is not required for patients with primary AI, as hydrocortisone doses of more than 50 mg/day have sufficient action at the mineralocorticoid receptor \[[@CR32]\], although an increase to 100 μg/day of fludrocortisone has been advocated in severe hypotension. As soon as the clinical condition allows, steroid infusion should be reduced accordingly, in order to avoid undesired detrimental effects. Finally, a very important recommendation comes from the increasing concern over the disseminated thromboembolic disease observed in severe COVID-19. Given the coagulation abnormalities associated with GC use \[[@CR33]\], added to that of immune hyperactivation, endothelial disfunction and hepatic impairment observed in COVID-19, we strongly recommend introducing heparin early in AI patients \[[@CR34]\], as soon as the symptoms evolve from mild to moderate or severe disease (4000 U every 12 h).

SARS-CoV2 pandemic has reignited the debate on GC therapy in lung injury, and many scientific panels are working in these fateful hours to investigate their efficacy in treating COVID-19-related pneumonia. Outside all of this, and given the severity of COVID-19-associated syndrome, this opinion aims to underline that clinicians must not overlook the fact that AI patients depend on exogenous GC therapy for adequate stress response even to mild illness. In summary, available evidences on tailoring of GC stress regimens in COVID-19 are still weak and a more evidence-based approach is required to draw a definitive standardized protocol. The pathophysiology of immune response and systemic complications associated with infection set the pace, and treatment strategy should be adapted to the patient's clinical stage. For AI patients suspected to have COVID-19, who have mild upper respiratory track symptoms and no lung impairment, doubling the usual dose of hydrocortisone (alongside adequate fluid replacement) in a circadian fashion seems a safe measure to preserve the early activation of the immune response. The latter is also because symptoms are not specific and may last, even if minor, for 2 weeks or more. However, as soon as symptoms worsen, it is advisable to further increase the dose up to 100 mg, commence thromboembolic prophylaxis and consider prompt hospitalization as the condition could deteriorate within few hours. In hospital, parenteral treatment with high doses (200 mg) of continuous intravenous hydrocortisone is only required following evolution towards a critical stage (rapid drop in oxygenation) or adrenal crisis (Fig. [1](#Fig1){ref-type="fig"}).
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